Switching within glaucoma medication class

Current Opinion in Ophthalmology

Volumn 20, Issue 2, 2009, Pages 110-115

  Law, Simon K ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Class; Glaucoma; Medication; Switch; Therapy

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHAGAN P; APRACLONIDINE; BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIPIVEFRINE; DORZOLAMIDE; ECOTHIOPATE IODIDE; LATANOPROST; LEVOBUNOLOL; METHAZOLAMIDE; METIPRANOLOL; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL GFS; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

BEDTIME DOSAGE; BLURRED VISION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG FORMULARY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIPHORA; EYE COLOR; EYE TOXICITY; EYELASH; FEASIBILITY STUDY; GLAUCOMA; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TACHYCARDIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBONIC ANHYDRASE INHIBITORS; FEASIBILITY STUDIES; GLAUCOMA; HUMANS; PARASYMPATHOMIMETICS; PROSTAGLANDINS; RETREATMENT;

EID: 62849107395     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32831d1fc7     Document Type: Review

References (64)

1. van der Valk R, Webers GAB, Scheuten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. Ophthalmology 2005; 112:1177-1185.
2. Nordmann JP, Mertz B, Yannoulis NC, et al., Unoprostone Monotherapy Study Group-EU. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol 2002; 133:1-10.
3. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005; 112:262-266.
4. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of lantaoprost, bimatoprost, and travaprost in patients with elevated intraocular pressure: a 1 2-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135:688-703.
5. Gross JL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 2008; 17:217-222.
6. Law SK, Song J, Fang E, et al. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology 2005; 112:2123-2130.
7. Cantor LB, Hoop J, Wudunn D, et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol 2007; 91:629-632.
8. Woodward DF, Krauss AH, Wang JW, et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanotamides) in the feline iris. Br J Pharmacol 2007; 150:342-352.
9. Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 2007; 48:4107-4115.
10. Romano MR, Lograno MD. Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. Invest Ophthalmol Vis Sci 2007; 48:3677-3682.
11. Ota T, Aihara M, Saeki T, et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci 2006; 47:3395-3399.
12. Crowston JG, Lindsey JD, Morris CA, et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci 2005; 46:4571-4577.
13. Rossetti L, Gandolfi S, Traverso C, et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma 2006; 15:238-243.
14. lkeda Y, Mori K, Ishibashi T, et al. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol 2006; 50:153-157.
15. Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 2007; 114:1039-1045.
16. Peng HB, Zahary MN, Tajudin LS, et al. A novel single nucleotide polymorphism, IVS2-97A>T, in the prostaglandin F2alpha receptor gene was identified among the Malaysian patients with glaucoma. Kobe J Med Sci 2007; 53:49-52.
17. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001; 18:110-121.
18. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132:472-484.
19. Noecker RS, Dirks MS, Choplin NT, et al., Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and lantanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135:55-63.
20. Stewart WC, Kolker AE, Stewart JA, et al. Conjunctical hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003; 135:314-320.
21. Chiba T, Kashiwagi K, Chiba N, et al. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br J Ophthalmol 2003; 87:956-959.
22. McCarey BE, Kapik BM, Kane FE, Unoprostone Monotherapy Study Group. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15% Ophthalmology 2004; 111:1480-1488.
23. Lewis RA, Katz GJ, Weiss MJ, et al., Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007; 16:98-103.
24. Gaul GR, Will NJ, Brubaker RF. Comparison of a noncardioselective ss-adrenergic blocker and a cardioselective blocker in reducing aqueous flow in humans. Arch Ophthalmol 1989; 107:1308-1311.
25. Collignon-Brach J. Long-term effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol 1994; 38 (Suppl):149-155.
26. Stewart RH, Kimbrough RL, Ward RL. Betaxolol versus timolol: a 6-month double-blind comparison. Arch Ophthalmol 1986; 104:44-48.
27. Brooks AMV, Burdon JGW, Gillies WE. The significance of reactions to betaxolol reported by patients. Aust N Z J Ophthalmol 1989; 17:353-355.
28. Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984; 97:86-92.
29. Van Buskirk EM, Weinreb RN, Berry DP, et al. Betaxolol in patients with glaucoma and asthma. Am J Ophthalmol 1986; 101:531-534.
30. Weinreb RN, van Buskirk EM, Chemiack R, Drake MM. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol 1988; 106:162-167.
31. Ananthanarayan CR, Vaile SJ, Feldman F. Acute episode of asthma following topical administration of betaxolol eye-drops. Can J Ophthalmol 1993; 28: 80-81.
32. Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol. Am J Ophthalmol 1986; 102:274-275.
33. Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol or plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1993; 116:600-611.
34. Netland PA, Weiss HS, Stewart WC, et al. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol 1997; 123:465-477.
35. Letchinger SL, Frohlichstein D, Glieser DK, et al. Can the cone of timiolol or the freq of its administration be reduced? Ophthalmology 1993; 100:1259-1262.
36. Soil DB. Evaluation of timolol in chronic open angle glaucoma: once a day versus twice a day. Arch Ophthalmol 1980; 98:2178-2181.
37. Rosenlund EF. The IOP lowering effect of timolol in gel-forming solution [published correction appears in Acta Ophthalmol Scan 1996; 74:416]. Acta Ophthalmol Scand 1996; 74:160-162.
38. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthlamol 1984; 102: 551-553.
39. Schadlu R, Maus TL, Nau CB, Brubaker RF. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol 1998; 116:1441-1444.
40. Barnes SD, Campagna JA, Dirks MS, Doe EA. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0% Ophthalmology 1999; 106:2033-2037.
41. Chevrier RL, Assalian A, Duperré J, Lesk MR. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevations following anterior segment laser procedures. Ophthalmic Surg Lasers 1999; 30:199-204.
42. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41(Suppl 1):S27-S37.
43. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115:847-852.
44. Gieser SC, Juzych M, Robin AL, et al. Clinical pharmacology of adrenergic drugs. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas, glaucoma therapy. St Louis: Mosby-Year Book; 1996. pp. 1425-1448.
45. Thompson CD, Macdonald TL, Garst ME, et al. Mechanism of adrenergic induced allergy bioactivation and antigen formation. Exp Eye Res 1997; 64:767-773.
46. Williams GC, Orengo-Nania S, Gross RL Incidence of brimonidine allergy in patients previously allergic to a apraclonidine. J Glaucoma 2000; 9:235-238.
47. Gordon RN, Liebmann JM, Greenfield DS, et al. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy. Eye 1998; 12 (Pt 4):697-700.
48. Shin DH, Glover BK, Cha SC, et al. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am J Ophthalmol 1999; 127: 511-515.
49. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002; 11:119-126.
50. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115:45-49.
51. Friedman Z, Krupin T, Becker B. Ocular and systemic effects of acetazolamide in nephrectomized rabbits. Invest Ophthalmol Vis Sci 1982; 23:209-213.
52. Brechue WF, Maren TH. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion. Exp Eye Res 1993; 57:67-78.
53. Hutzelmann JE, Polis AB, Michael AJ, Adamsons IA. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group. Acta Ophthalmol Scand 1998; 76:717-722.
54. Rosenberg LF, Krupin T, Tang LQ, et al. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology 1998; 105:88-92.
55. Maren TH, Haywood JR, Chapman SK, et al. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci 1977; 16:730-742.
56. Gabelt BT, Kaufman PL. Aqueous humor hydrodynamics. In: Kaufman PJ, Aim A, editors. Adler's physiology of the eye clinical application, 10th ed. St Louis: Mosby; 2003. pp. 238-242.
57. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000; 44 (Suppl 2):S141-S145.
58. Seong GJ, Lee SC, Lee JH, et al. Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Ophthalmologica 2001; 215:188-191.
59. Michaud JE, Friren B, International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132:235-243.
60. March WF, Stewart RM, Mandell AI, Bruce LA. Duration of effect of pilocarpine gel. Arch Ophthalmol 1982; 100:1270-1271.
61. Quigley HA, Pollack IP, Harbin TS Jr. Pilocarpine Ocuserts. Long-term clinical trials and selected pharmacodynamics. Arch Ophthalmol 1975; 93:771-775.
62. Worthen DM, Zimmerman TJ, Wind CA. An evaluation of the pilocarpine Ocusert. Invest Ophthalmol 1974; 13:296-299.
63. Hillman JS, Walker A, Davies EM. Management of chronic glaucoma with pilocarpine Ocuserts. Trans Ophthalmol Soc U K 1977; 97:206-209.
64. Brown HS, Meltzer G, Merrill RC, et al. Visual effects of pilocarpine in glaucoma comparative study of administration by eyedrops or by ocular therapeutic systems. Arch Ophthalmol 1976; 94:1716-1719.